Notably, a marked difference was identified between the SLIT2 promoter hypermethylated and non-hypermethylated groups in CML patients grouped by clinical stage (P < 0.001, Table 1). This evidence concerns the gene SLIT2 and chronic myelogenous leukemia, BCR-ABL1 positive.